Every clinical trial begins with a patient enrollment target and a timeline someone believes is achievable. Most trials fall behind within the first quarter. The challenge is rarely a lack of eligible patients. More often, it is the inability to identify and match those patients to the right studies quickly enough.
Drug development can take 10 to 20 years, while patent exclusivity begins counting down as soon as it is granted. Every month spent waiting for enrollment can reduce commercial opportunity, increase development costs, and delay access to potentially life-changing treatments for patients.
The industry has invested heavily in new technologies, larger site teams, and additional oversight. Yet enrollment delays remain one of the most persistent challenges in clinical research. As enrollment pressures continue to grow, leading clinical organizations are turning to AI-assisted patient matching to bridge that gap.
The Real Reason Trials Fall Behind
The instinct in most enrollment conversations is to look at site performance metrics, investigator networks, or patient awareness campaigns. Those factors matter. But they sit on top of a more fundamental fragility that rarely gets named directly.
The root cause is a matching problem: the information needed to identify eligible patients exists, but the systems and processes for connecting it do not work at the speed or scale that modern trial operations demand.
That gap often shows up in three distinct layers.
1. Unstructured Eligibility Criteria
Eligibility criteria are written for regulatory reviewers, not for rapid clinical application.
They live in lengthy, free-text protocols full of conditional logic, cross-referenced definitions, and exception clauses that require active interpretation. There is no structured, machine-readable version a system can reason over directly.
A coordinator matching a patient against an inclusion or exclusion criterion is doing interpretive work, sentence by sentence, patient by patient, often under time pressure.
2. Fragmented Patient Data
The information needed to determine patient eligibility is almost never in one place.
EHR records, disease registries, lab systems, genomic databases, and clinical notes each hold a piece of the picture. No single system surfaces a complete view for matching.
A coordinator working within one platform may have no visibility into the data sitting in another, even within the same institution. A patient who meets every inclusion criterion may be invisible to the person doing the screening simply because they don’t have access to the system housing that patient’s data.
At a multi-site trial level, this fragmentation multiplies. The practical result is that coordinators are making eligibility judgments based on incomplete information, and no one has a reliable mechanism to know how often that is happening.
3. Manual Cross-Referencing
Manual cross-referencing is the process most sites are still using to connect patient data to eligibility criteria.
The process is slow by design as the coordinator must hold both the protocol logic and the patient record in view simultaneously, working through each criterion in sequence. It is also error-prone in ways that are difficult to detect and audit.
More importantly, the process does not scale. Sites managing multiple concurrent trials are not just doing this work once per patient. They are doing it repeatedly, across overlapping patient populations, with limited time and no automated support. The knowledge management burden compounds faster than headcount can absorb it.
Beyond Patient Matching: The Knowledge Access Problem
Finding eligible patients is only one side of the equation. Even when enrollment processes improve, clinical teams still face a significant challenge: accessing the information they need to execute trials consistently and compliantly.
Protocols, SOPs, monitoring plans, and regulatory guidance are often scattered across PDFs, shared drives, email threads, and disconnected knowledge repositories. Multiple document versions can exist simultaneously, creating uncertainty about which guidance is current.
As a result, coordinators may reference outdated protocols, sites may interpret eligibility criteria differently, and newly onboarding staff can spend weeks navigating complex documentation before becoming fully productive.
The impact extends well beyond administrative inefficiency. Inconsistent interpretation across sites can introduce variability that affects data quality. Meanwhile, missing or inaccessible information can increase protocol deviations and create audit risks. These issues rarely appear on enrollment dashboards, yet they directly influence trial performance, compliance, and operational consistency.
This is the reality many clinical operations teams face today. Not a lack of expertise or oversight, but a growing volume of critical knowledge spread across systems that were never designed to work together.
How AI-Assisted Patient Matching Solve The Problem
The conversation around AI in clinical trials has generated more aspiration than clarity. The useful question is not whether AI can improve enrollment. It is how a specific AI architecture actually handles the knowledge access gap described above.
To address this challenge, leading life sciences organizations are increasingly adopting AI-assisted patient matching powered by Retrieval-Augmented Generation (RAG) architectures. These approaches connect trial protocols, patient data, and clinical knowledge sources through a coordinated multi-agent workflow.
Rather than relying on a single AI model, the approach uses various specialized agents to perform different tasks while maintaining full traceability throughout the process.
1. Protocol Interpretation
The workflow begins with the trial protocol. A protocol interpretation agent retrieves eligibility criteria from the study documentation and transforms complex free-text requirements into structured rules that can be applied consistently. This helps operationalize inclusion and exclusion criteria that would otherwise require extensive manual review and interpretation.
2. Patient Data Retrieval
The patient data retrieval agent gathers candidate information from connected sources such as EHRs, patient registries, laboratory systems, and clinical notes. Instead of requiring coordinators to search across multiple systems, the agent assembles the relevant information needed to assess eligibility.
3. Eligibility Reasoning
The eligibility reasoning agent compares patient attributes against the protocol criteria to identify potential matches. It can also surface near-matches that may warrant additional review, helping clinical teams focus their attention on the most promising candidates while reducing the manual burden of screening large patient populations.
4. Clinical Oversight
Not every case is straightforward. When eligibility depends on clinical interpretation or when information is incomplete, the clinical oversight agent routes the case to a coordinator or clinician for review. Human judgment remains central to the process, ensuring that enrollment decisions involving clinical expertise stay under human control.
5. Audit and Compliance
The audit and compliance agent records each retrieval step, reasoning outcome, and workflow decision. This creates a complete and traceable record that supports inspection readiness and regulatory defensibility throughout the recruitment process.
Governance Is the Real Differentiator
Clinical leaders who have been in this industry long enough have watched AI tools arrive with ambitious promises and struggle when they encounter the realities of compliance, governance, and regulatory oversight.
As organizations adopt AI-assisted patient matching, the differentiator will not be the sophistication of the AI itself. It will be the governance framework surrounding it. The most successful implementations are designed with controls that ensure recommendations are transparent, traceable, and subject to human oversight.
Enterprise data stays separate from model training. Sensitive protocol information and patient data remain under organizational control and are not incorporated into model weights.
Access is controlled and governed. Role-based permissions and configurable workflows ensure users only access the information and actions appropriate to their responsibilities.
Every interaction is traceable. Retrieval steps, data sources, protocol references, and reasoning outputs are captured to create a complete, inspection-ready audit trail.
Human judgment remains in control. AI can identify potential matches and assemble supporting evidence, but clinicians and study coordinators remain responsible for reviewing and confirming decisions.
In clinical research, the value of AI is not measured by how quickly it generates a recommendation, but by how confidently teams can trust and validate it. As AI-assisted patient matching becomes more widely adopted, organizations that pair AI capabilities with strong governance, traceability, and human oversight will be best positioned to realize its benefits in regulated environments.
Bottom Lines
AI-assisted patient matching is becoming a practical response to one of clinical research’s most persistent bottlenecks: finding the right participants quickly, while maintaining compliance. As trials become more complex and data sources more fragmented, clinical teams need a more governed way to bridge the knowledge access gap.
KMS has partnered with SAS to help life sciences organizations bring that capability into clinical trial environments through SAS Retrieval Agent Manager (RAM).
SAS RAM combines Retrieval-Augmented Generation (RAG) with multi-agent orchestration to help teams unlock knowledge from unstructured clinical data, support patient eligibility evaluation, and automate knowledge-driven workflows while maintaining governance, traceability, and human oversight.
A workflow like this can be implemented with KMS and SAS RAM:
- Access trusted knowledge across different clinical and operational systems
- Interpret complex trial requirements from unstructured documentation
- Match patients to study criteria using AI-assisted retrieval and reasoning workflows
- Automate processes through coordinated multi-agent orchestration
- Make informed clinical decisions with built-in dashboard and oversight capabilities
Ready to see how governed AI-assisted patient matching can help accelerate enrollment without compromising compliance? Talk to KMS to explore SAS RAM for clinical trials.
References
1. Tufts Center for the Study of Drug Development
Stat used: $500,000 lost for each day of clinical trial delay, due to unrealized prescription drug or biologic sales. Source: New Estimates on the Cost of a Delay Day in Drug Development
2. Journal Of Medical Internet Research
Stat used: 80% of trials fail to meet the initial enrollment target and timeline, and these delays can result in lost revenue of as much as US $8 million per day for drug developing companies. Source: Online Patient Recruitment in Clinical Trials: Systematic Review and Meta-Analysis